Physician profile
Derek Mori
NPI 1164093969
$3,308.16
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $544 · 2022: $1,076 · 2023: $1,375 · 2024: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,689.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,688.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $592.41 | 2021-2024 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $400.69 | 2021-2023 | Mounjaro, Jardiance, Emgality |
| Amgen INC. | $400.03 | 2021-2024 | Prolia, Evenity, Repatha |
| Abbvie INC. | $286.40 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $241.55 | 2022-2023 | Jardiance |
| Philips North America LLC | $217.00 | 2023-2024 | (5050) Ext Holter, (5044) Mcot |
| Mylan Specialty L.P. | $188.06 | 2021-2022 | |
| Pfizer INC. | $163.47 | 2023-2024 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $140.79 | 2022 | |
| Glaxosmithkline, LLC. | $132.82 | 2021-2023 | Shingrix, Arexvy, Pediarix |
| Idorsia Pharmaceuticals US INC | $104.09 | 2023 | Quviviq |
| Organon LLC | $89.67 | 2022-2023 | Nexplanon |
| Bayer Healthcare Pharmaceuticals INC. | $86.13 | 2023 | |
| Otsuka America Pharmaceutical, INC. | $46.23 | 2023 | Rexulti |
| Exact Sciences Corporation | $37.32 | 2023 | Cologuard Collection Kit |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $36.60 | 2022 | |
| Harmony Biosciences LLC | $29.91 | 2023 | Wakix |
| Seqirus USA INC | $29.48 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $23.16 | 2023 | Farxiga |
| Alkermes, INC. | $22.60 | 2021 | |
| Dexcom, INC. | $21.06 | 2023 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $18.69 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Mori listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.